INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Public company

IMCRImmunocore Holdings plc

CIK 0001671927

EDGAR filingsOpen in network
Disclosed transactions31
Buys / sells0 / 8
Max Insider Score34
Connections9with evidence

IMCR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
PW
Pao WilliamDirector
IMCRImmunocore Holdings plc
Grant or award
A—
27.5K sh
May 27, 2026May 28, 2026
traded May 27, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Kaul SiddharthDirector · May 28, 2026
  • ← Insider ofevidence
    Herbst Roy StevenDirector · May 28, 2026
  • ← Insider ofevidence
    Ratcliffe Peter JohnDirector · May 28, 2026
9
RJ
Ratcliffe Peter JohnDirector
IMCRImmunocore Holdings plc
Grant or award
A
—
27.5K sh
May 27, 2026
May 28, 2026
traded May 27, 2026
+1d
SEC FORM 4

Evidence

9
HS
Herbst Roy StevenDirector
IMCRImmunocore Holdings plc
Grant or award
A—
27.5K sh
May 27, 2026May 28, 2026
traded May 27, 2026
+1dSEC FORM 4

Evidence

9
KS
Kaul SiddharthDirector
IMCRImmunocore Holdings plc
Grant or award
A—
27.5K sh
May 27, 2026May 28, 2026
traded May 27, 2026
+1dSEC FORM 4

Evidence

9
BI
Bell John IrvingDirector
IMCRImmunocore Holdings plc
Grant or award
A—
27.5K sh
May 27, 2026May 28, 2026
traded May 27, 2026
+1dSEC FORM 4

Evidence

9
SA
St Leger Tina AmberCHIEF HR OFFICER
IMCRImmunocore Holdings plc
Option exercise
M—
2,119 sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

10
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise
M—
11.8K sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

34
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale
SELL$193K
5,965 sh
Feb 18, 2026Feb 19, 2026
traded Feb 18, 2026
+1dSEC FORM 4

Evidence

2
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise
M—
11.8K sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

9
CA
Coy Travis AlanChief Financial Officer
IMCRImmunocore Holdings plc
Grant or award
A—
95.6K sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

9
CA
Coy Travis AlanChief Financial Officer
IMCRImmunocore Holdings plc
Grant or award
A—
33.4K sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

21
SA
St Leger Tina AmberCHIEF HR OFFICER
IMCRImmunocore Holdings plc
Option exercise
M—
2,119 sh
Feb 17, 2026Feb 19, 2026
traded Feb 17, 2026
+2dSEC FORM 4

Evidence

34
SA
St Leger Tina AmberCHIEF HR OFFICER
IMCRImmunocore Holdings plc
Open-market sale
SELL$32K
1,000 sh
Feb 18, 2026Feb 19, 2026
traded Feb 18, 2026
+1dSEC FORM 4

Evidence

1
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M$547K
31.3K sh
Dec 4, 2025Dec 8, 2025
traded Dec 4, 2025
+4dSEC FORM 4

Evidence

22
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale · 10b5-1 plan
SELL$1.26M
31.3K sh
Dec 4, 2025Dec 8, 2025
traded Dec 4, 2025
+4dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M$9,987
572 sh
Dec 5, 2025Dec 8, 2025
traded Dec 5, 2025
+3dSEC FORM 4

Evidence

13
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale · 10b5-1 plan
SELL$23K
572 sh
Dec 5, 2025Dec 8, 2025
traded Dec 5, 2025
+3dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M—
31.3K sh
Dec 4, 2025Dec 8, 2025
traded Dec 4, 2025
+4dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M—
572 sh
Dec 5, 2025Dec 8, 2025
traded Dec 5, 2025
+3dSEC FORM 4

Evidence

10
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M$1.21M
69.4K sh
Nov 26, 2025Dec 1, 2025
traded Nov 26, 2025
+5dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M—
5,521 sh
Nov 28, 2025Dec 1, 2025
traded Nov 28, 2025
+3dSEC FORM 4

Evidence

1
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M—
69.4K sh
Nov 26, 2025Dec 1, 2025
traded Nov 26, 2025
+5dSEC FORM 4

Evidence

16
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale · 10b5-1 plan
SELL$221K
5,521 sh
Nov 28, 2025Dec 1, 2025
traded Nov 28, 2025
+3dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M$96K
5,521 sh
Nov 28, 2025Dec 1, 2025
traded Nov 28, 2025
+3dSEC FORM 4

Evidence

28
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale · 10b5-1 plan
SELL$2.78M
69.4K sh
Nov 26, 2025Dec 1, 2025
traded Nov 26, 2025
+5dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M—
18.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M—
100 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

19
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale · 10b5-1 plan
SELL$721K
18.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

1
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M$315K
18.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

17
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Open-market sale · 10b5-1 plan
SELL$4,000
100 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

0
BM
Berman David MHEAD OF R&D
IMCRImmunocore Holdings plc
Option exercise · 10b5-1 plan
M$1,746
100 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Pao WilliamDirector · May 28, 2026
  • ← Insider ofevidence
    Bell John IrvingDirector · May 28, 2026
  • ← Insider ofevidence
    Coy Travis AlanChief Financial Officer · Feb 19, 2026
  • ← Insider ofevidence
    St Leger Tina AmberCHIEF HR OFFICER · Feb 19, 2026
  • ← Insider ofevidence
    Berman David MHEAD OF R&D · Nov 26, 2025
    • Data sources
    SEC FORM 46m ago
    HOUSE PTR6m ago
    SEC 13F6m ago
    ROBINHOOD CHAIN6m ago